Anthony G. Quinn Purchases 85,000 Shares of Generation Bio Co. (NASDAQ:GBIO) Stock

Generation Bio Co. (NASDAQ:GBIO - Get Free Report) Director Anthony G. Quinn acquired 85,000 shares of the business's stock in a transaction that occurred on Monday, January 13th. The stock was acquired at an average cost of $0.97 per share, with a total value of $82,450.00. Following the completion of the acquisition, the director now owns 299,286 shares in the company, valued at $290,307.42. This trade represents a 39.67 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Generation Bio Price Performance

GBIO stock traded down $0.04 during mid-day trading on Tuesday, hitting $0.88. 1,241,984 shares of the stock were exchanged, compared to its average volume of 728,243. The business has a fifty day moving average price of $1.35 and a 200 day moving average price of $2.13. Generation Bio Co. has a 12 month low of $0.75 and a 12 month high of $4.65. The stock has a market capitalization of $58.78 million, a price-to-earnings ratio of -0.40 and a beta of 2.72.

Analysts Set New Price Targets

A number of research firms have recently commented on GBIO. Wedbush reaffirmed an "outperform" rating and issued a $5.00 price target on shares of Generation Bio in a report on Thursday, November 7th. Needham & Company LLC dropped their price objective on Generation Bio from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th.

Institutional Investors Weigh In On Generation Bio

Several institutional investors have recently bought and sold shares of GBIO. Baker BROS. Advisors LP increased its position in Generation Bio by 61.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,944,945 shares of the company's stock valued at $4,804,000 after purchasing an additional 737,988 shares during the period. Barclays PLC increased its position in shares of Generation Bio by 165.5% during the third quarter. Barclays PLC now owns 76,430 shares of the company's stock valued at $189,000 after buying an additional 47,639 shares during the period. Bank of New York Mellon Corp increased its position in shares of Generation Bio by 31.2% during the second quarter. Bank of New York Mellon Corp now owns 186,756 shares of the company's stock valued at $527,000 after buying an additional 44,378 shares during the period. American Century Companies Inc. raised its stake in Generation Bio by 199.3% in the second quarter. American Century Companies Inc. now owns 31,786 shares of the company's stock worth $90,000 after buying an additional 21,167 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Generation Bio in the third quarter worth about $42,000. 95.22% of the stock is currently owned by hedge funds and other institutional investors.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.